Hybrigenics Receives Authorization To Accelerate Inecalcitol Dose Escalation In Phase II Trial For Hormone-refractory Prostate Cancer

Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced that France’s regulatory agency AFSSAPS has authorized the company to increase inecalcitol dosage in Hybrigenics’ Phase II clinical trial currently underway for patients suffering from hormone-refractory prostate cancer.

More: continued here

Filed under: Prostate on June 19th, 2008